Palisade Bio Inc. (PALI)
Palisade Bio Inc. (PALI) Stock Price, Analysis & Data
| Bid | 1.54 |
| Market Cap | 341.57M |
| Revenue (ttm) | 500K |
| Net Income (ttm) | -31.94M |
| Beta | 1.54 |
| EPS (ttm) | 0.65 |
| PE Ratio (ttm) | 3.02 |
| Forward PE | -7.07 |
| P/B (ttm) | 2.80 |
| P/S (ttm) | 683.14 |
| Earnings Date | n/a |
| Ask | 2.5 |
| Volume | 2,332,222 |
| Avg. Volume (20D) | 3,157,525 |
| Open | 2.14 |
| Previous Close | 2.14 |
| Day's Range | 1.95 - 2.18 |
| 52-Week Range | 0.53 - 2.86 |
| Analyst | n/a |
| Price Target | 8 (308.16%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PALI
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research c...
Financial Performance
In 2025, Palisade Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -16.78M, an increase of 16.23%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for PALI stock is "null". The 12-month stock price forecast is 8, which is upside of 308.16% from the latest price.
Stock Forecasts
